Longitudinally extensive transverse myelitis

Current Opinion in Neurology

Volumn 27, Issue 3, 2014, Pages 279-289

  Tobin, W Oliver ^a   Weinshenker, Brian G ^a   Lucchinetti, Claudia F ^a  

^a MAYO CLINIC   (United States)

Author keywords

longitudinally extensive transverse myelitis; myelitis; neuromyelitis optica

Indexed keywords

AQUAPORIN 4; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VASOPRESSIN; AUTOANTIBODY; ECULIZUMAB; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

CELL MEMBRANE; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; DYSPHAGIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HICCUP; HUMAN; HYPOGEUSIA; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LONGITUDINALLY EXTENSIVE TRANSVERSE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PLASMAPHERESIS; PROTEIN EXPRESSION; REVIEW; SPINAL CORD BIOPSY; VOMITING; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FLOW CYTOMETRY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; SEROLOGY; SJOGREN'S SYNDROME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AQUAPORIN 4; AUTOANTIBODIES; AZATHIOPRINE; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYELITIS, TRANSVERSE; NEUROMYELITIS OPTICA; SEROLOGIC TESTS; SJOGREN'S SYNDROME;

EID: 84900431997     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000093     Document Type: Review

References (77)

1. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 2002; 59:499-505.
2. Tartaglino LM, Friedman DP, Flanders AE, et al. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995; 195:725-732.
3. Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59:566-569.
4. Debette S, de Seze J, Pruvo JP, et al. Long-term outcome of acute and subacute myelopathies. J Neurol 2009; 256:980-988.
5. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125 (Pt 7):1450-1461.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-2112.
7. Devic E, editor. Myélite aiguë dorso-lombaire avec névrite optique: Autopsie. Congrès français de médecine (Premiere Session; Lyon, 1894; procès-verbaux, mé moires et discussions; publiés par M le Dr L Bard); 1895; Paris: Asselin et Houzeau, Louis Savy.
8. Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation 2013; 10:8.
9. Nakamura M, Miyazawa I, Fujihara K, et al. Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study. J Neurol 2008; 255:163-170.
10. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007; 68:603-605.
11. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-1489.
12. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 2013; 81:1197-1204.
13. Iones A, Howard J. Hypogeusia as a symptom of neuromyelitis optica spectrum disorder. Mult Scler 2013; 19:1548-1549.
14. Lotze TE, Northrop JL, Hutton GJ, et al. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008; 122:e1039-e1047.
15. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72:712-717.
16. Jiao Y, Fryer JP, Lennon VA, et al. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol 2014;71:48-54.
17. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012; 78: 665-671. [discussion 9]
18. Hinson SR, Pittock SJ, Lucchinetti CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69:1-11.
19. Nicchia GP, Nico B, Camassa LMA, et al. The role of aquaporin-4 in blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 2004; 129:935-945.
20. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130 (Pt 5):1194-1205.
21. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130 (Pt 5):1224-1234.
22. Sato DK, Misu T, Rocha CF, et al. Aquaporin-4 antibody-positive myelitis initially biopsied for suspected spinal cord tumors: diagnostic considerations. Mult Scler 2014; 20:621-626.
23. Lucchinetti CF, Guo Y, Popescu BF, et al. The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 2014;24:83-97.
24. Hinson SR, Romero MF, Popescu BF, et al. Molecular outcomes of neuro-myelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 2012; 109:1245-1250.
25. Matiello M, Schaefer-Klein J, Sun D, Weinshenker BG. Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 2013;70:1118-1125.
26. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130:1235-1243.
27. Apiwattanakul M, McKeon A, Fryer JP, et al. AQP4-IgG immunoprecipitation assay optimization. Clin Chem 2009; 55:592-594.
28. Li J, Patil RV, Verkman AS. Mildly abnormal retinal function in transgenic mice without Muller cell aquaporin-4 water channels. Invest Ophthalmol Vis Sci 2002; 43:573-579.
29. Lu DC, Zhang H, Zador Z, Verkman AS. Impaired olfaction in mice lacking aquaporin-4 water channels. FASEB J 2008; 22:3216-3223.
30. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008; 10:55-66.
31. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46:878-886.
32. Kim SH, Kim W, Huh SY, et al. Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol 2013; 9:36-42.
33. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13:128-132.
34. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immu-noglobulin. J Clin Immunol 2013; 33 (Suppl 1):S33-S37.
35. Elsone L, Panicker J, Mutch K, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014; 20:501-504.
36. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 2013; 28:65-72.
37. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51:1219-1220.
38. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77:659-666.
39. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66:1128-1133.
40. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270-1272.
41. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65:1443-1448.
42. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70:1110-1107.
43. Nakashima I, Takahashi T, Cree BA, et al. Transient increases in antiaquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 2011; 18:997-998.
44. Pittock SJ, Lennon VA, McKeon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 2013; 12:554-562.
45. Komai T, Shoda H, Yamaguchi K, et al. Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report. Mod Rheumatol 2013. [Epub ahead of print]
46. Araki M, Aranami T, Matsuoka T, et al. Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 2013; 23:827-831.
47. Ayzenberg I, Kleiter I, Schroder A, et al. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 2013; 70:394-397.
48. Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol 2013; 23:684-695.
49. Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica antiaquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol 2013; 73:77-85.
50. Kahlenberg JM. Neuromyelitis optica spectrum disorder as an initial presenta-tionofprimarySjogren'ssyndrome.SeminArthritis Rheum2011;40:343-348.
51. Espinosa G, Mendizabal A, Minguez S, et al. Transverse myelitis affecting more than 4 spinal segments associated with systemic lupus erythematosus: clinical, immunological, and radiological characteristics of 22 patients. Semin Arthritis Rheum 2010; 39:246-256.
52. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65:78-83.
53. Woodhall M, Coban A, Waters P, et al. Glycine receptor and myelin oligo-dendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica. J Neurol Sci 2013; 335:221-223.
54. Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79:1273-1277.
55. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474-481.
56. Flanagan EP, Marsh RW, Weinshenker BG. Teaching neuroimages: 'pan-cake-like' gadolinium enhancement suggests compressive myelopathy due to spondylosis. Neurology 2013; 80:e229.
57. Sohn M, Culver DA, Judson MA, et al. Spinal cord neurosarcoidosis. Am J Med Sci 2014; 347:195-198.
58. Flanagan EP, Hunt CH, Lowe V, et al. [18F]-Fluorodeoxyglucose-positron emission tomography in patients with active myelopathy. Mayo Clin Proc 2013; 88:1204-1212.
59. Huang JF, Aksamit AJ, Staff NP. MRI and PET imaging discordance in neurosarcoidosis. Neurology 2012; 79:1070.
60. Joseph FG, Scolding NJ. Sarcoidosis of the nervous system. Practical Neurol 2007; 7:234-244.
61. Sodhi M, Pearson K, White ES, Culver DA. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009; 103:268-273.
62. Dragnev D, Barr D, Kulshrestha M, Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. Br Med J Case Rep 2013; bcr2013200552.
63. Burns AM, Green PJ, Pasternak S. Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 2012; 39:289-293.
64. Graham D, McCarthy A, Kavanagh E, et al. Teaching NeuroImages: long-itudinally extensive transverse myelitis in neuro-Behcet disease. Neurology 2013; 80:e189-e190.
65. Siva A, Kantarci OH, Saip S, et al. Behcet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248:95-103.
66. Ait Ben Haddou EH, Imounan F, Regragui W, et al. Neurological manifestations of Behcet's disease: evaluation of 40 patients treated by cyclophos-phamide. Rev Neurol (Paris) 2012; 168:344-349.
67. Shugaiv E, Tuzun E, Mutlu M, et al. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behcet's disease with par-enchymal involvement: presentation of four cases. Clin Exp Rheumatol 2011; 29 (4 Suppl 67):S64-S67.
68. Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clin Rheumatol 2011; 30:1007-1012.
69. Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012; 30 (3 Suppl 72):S73-S75.
70. Shapiro LS, Farrell J, Haghighi AB. Tocilizumab treatment for neuro-Behcet's disease: the first report. Clin Neurol Neurosurg 2012; 114:297-298.
71. Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelo-pathy: clinical course and neuroimaging clues. Neurology 2011; 76:2089-2095.
72. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol 2008; 63:531-534.
73. Atkinson JL, Miller GM, Krauss WE, et al. Clinical and radiographic features of dural arteriovenous fistula, a treatable cause of myelopathy. Mayo Clin Proc 2001; 76:1120-1130.
74. Wolf K, Schmitt-Mechelke T, Kollias S, Curt A. Acute necrotizing encephalopathy (ANE1): rare autosomal-dominant disorder presenting as acute trans verse myelitis. J Neurol 2013; 260:1545-1553.
75. Raut TP, Singh MK, Garg RK, Naphade PU. Subacute sclerosing panence-phalitis presenting as neuromyelitis optica. Br Med J Case Rep 2012; bcr2012006764.
76. Kumar N, Ahlskog JE, Klein CJ, Port JD. Imaging features of copper deficiency myelopathy: a study of 25 cases. Neuroradiology 2006; 48:78-83.
77. van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006; 66:494-498.